These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 1097091)
1. Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography. Finj C; Sadée W Cancer Chemother Rep; 1975; 59(2 Pt 1):279-86. PubMed ID: 1097091 [TBL] [Abstract][Full Text] [Related]
2. Altered plasma kinetics of 5-FU at high dosage in rat and man. Schwartz PM; Turek PJ; Hyde CM; Cadman EC; Handschumacher RE Cancer Treat Rep; 1985 Jan; 69(1):133-6. PubMed ID: 3967255 [TBL] [Abstract][Full Text] [Related]
3. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer. Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177 [TBL] [Abstract][Full Text] [Related]
4. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123 [TBL] [Abstract][Full Text] [Related]
5. Determination of 5-fluorouracil in plasma by GC/MS using an internal standard. Applications to pharmacokinetics. Cano JP; Rigault JP; Aubert C; Carcassonne Y; Seitz JF Bull Cancer; 1979; 66(1):67-74. PubMed ID: 420949 [TBL] [Abstract][Full Text] [Related]
6. Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. McDermott BJ; van den Berg HW; Murphy RF Cancer Chemother Pharmacol; 1982; 9(3):173-8. PubMed ID: 7160054 [TBL] [Abstract][Full Text] [Related]
7. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Casale F; Canaparo R; Serpe L; Muntoni E; Pepa CD; Costa M; Mairone L; Zara GP; Fornari G; Eandi M Pharmacol Res; 2004 Aug; 50(2):173-9. PubMed ID: 15177306 [TBL] [Abstract][Full Text] [Related]
8. Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. Peer CJ; McManus TJ; Hurwitz HI; Petros WP J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jun; 898():32-7. PubMed ID: 22565063 [TBL] [Abstract][Full Text] [Related]
9. Determination of (plus or minus)-1, 2-bis(3, 5-dioxopiperazinyl) propane plasma levels in rats, rabbits, and humans by GLC and mass fragmentography. Sadée W; Staroscik J; Finn C; Cohen J J Pharm Sci; 1975 Jun; 64(6):998-1001. PubMed ID: 1133759 [TBL] [Abstract][Full Text] [Related]
10. Determination of ftorafur and 5-fluorouracil levels in plasma and urine. Wu AT; Schwandt HJ; Finn C; Sadée W Res Commun Chem Pathol Pharmacol; 1976 May; 14(1):89-102. PubMed ID: 935657 [TBL] [Abstract][Full Text] [Related]
11. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Coustère C; Mentré F; Sommadossi JP; Diasio RB; Steimer JL Cancer Chemother Pharmacol; 1991; 28(2):123-9. PubMed ID: 2060083 [TBL] [Abstract][Full Text] [Related]
12. Disposition of 5-fluorouracil after intravenous bolus doses of a commercial formulation to cancer patients. Sitar DS; Shaw DH; Thirlwell MP; Ruedy JR Cancer Res; 1977 Nov; 37(11):3981-4. PubMed ID: 908036 [TBL] [Abstract][Full Text] [Related]
13. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056 [TBL] [Abstract][Full Text] [Related]
14. Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs. Nakayama Y; Matsumoto K; Inoue Y; Katsuki T; Kadowaki K; Shibao K; Tsurudome Y; Hirata K; Sako T; Nagata N; Itoh H Anticancer Res; 2006; 26(5B):3983-8. PubMed ID: 17094430 [TBL] [Abstract][Full Text] [Related]
16. Conversion of a novel 5-fluorouracil (5-FU) derivative to 5-FU in rats. Takada K; Yoshikawa H; Muranishi S Res Commun Chem Pathol Pharmacol; 1983 Apr; 40(1):99-108. PubMed ID: 6867473 [TBL] [Abstract][Full Text] [Related]
17. Comparative determinations of 5-fluorouracil in plasma using GC/MS and HPLC. Aubert C; Luccioni C; Coassolo P; Sommadossi JP; Cano JP Arzneimittelforschung; 1981; 31(12):2048-53. PubMed ID: 7199295 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats. Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T J Pharmacol Toxicol Methods; 2014; 70(2):134-44. PubMed ID: 25072509 [TBL] [Abstract][Full Text] [Related]
19. Determination of 5-fluorouracil in plasma and liver after oral administration of 5'-deoxy-5-fluorouridine using gas chromatography-mass spectrometry. Odagiri H; Ichihara S; Semura E; Utoh M; Tateishi M; Kuruma I J Pharmacobiodyn; 1988 Apr; 11(4):234-40. PubMed ID: 2970537 [TBL] [Abstract][Full Text] [Related]
20. A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer. Climente-Martí M; Merino-Sanjuán M; Almenar-Cubells D; Jiménez-Torres NV J Pharm Sci; 2003 Jun; 92(6):1155-65. PubMed ID: 12761805 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]